Der Immuncheckpoint PD‐1/PD‐L1: Gibt es Therapieoptionen jenseits der Antikörper?
Markella Konstantinidou(University of California, San Francisco), Alexander Dömlingꝉ(Institute of Molecular and Translational Medicine), Tryfon Zarganes‐Tzitzikas(University of Groningen), Tad A. Holak(Jagiellonian University), Katarzyna Magiera‐Mularz(Jagiellonian University)
Cited by 4
Related Papers
Covalent inhibitors: a rational approach to drug discovery
|RSC Medicinal Chemistry|2020|375
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
|Oncotarget|2017|308
PROTACs– a game-changing technology
|Expert Opinion on Drug Discovery|2019|159
Molecular glues for protein-protein interactions: Progressing toward a new dream
|Cell chemical biology|2024|139
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
|Angewandte Chemie International Edition|2017|133